| olanzapine / Generic mfg. |
NCT00647972: Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg |
|
|
| Terminated | 1 | 32 | US | Olanzapine Tablets 20 mg, Zyprexa® Tablets 20 mg | Mylan Pharmaceuticals Inc | Healthy | 05/03 | | | |
NCT00648921: Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg |
|
|
| Completed | 1 | 30 | US | Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg | Mylan Pharmaceuticals Inc | Healthy | 07/03 | 07/03 | | |
NCT00647777: Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg |
|
|
| Completed | 1 | 32 | US | Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg | Mylan Pharmaceuticals Inc | Healthy | 07/03 | 07/03 | | |
NCT00255879: Movement Disorders Caused by Antipsychotic Drugs in Older Patients |
|
|
| Completed | 1 | 250 | US | Quetiapine, Risperidone, Olanzapine | University of California, San Diego, National Institute of Mental Health (NIMH) | Dyskinesia, Drug-Induced | 08/04 | 08/04 | | |
NCT00150215: A First In Human Study Of PF-00184562 In Healthy Volunteers |
|
|
| Completed | 1 | 18 | US | PF-00184562, Olanzapine | Pfizer, PPD | Schizophrenia | | 10/05 | | |
NCT01503437: Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition |
|
|
| Completed | 1 | 22 | RoW | Olanzapine OD Tablets 5 mg, Zyprexa Zydis | Dr. Reddy's Laboratories Limited | Fasting | 11/06 | 12/06 | | |
NCT01503450: Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition |
|
|
| Completed | 1 | 26 | RoW | Olanzapine OD Tablets 5 mg, Zyprexa Zydis | Dr. Reddy's Laboratories Limited | Fed | 12/06 | 12/06 | | |
NCT01556763: Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia |
|
|
| Completed | 1 | 21 | US | EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy | FORUM Pharmaceuticals Inc | Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases | 08/08 | 08/08 | | |
|
NCT00563992: Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder |
|
|
| Completed | 1 | 98 | US | Lithium, Valproic acid, Sodium valproate or valproic acid (Depakote) | New York State Psychiatric Institute, National Institute of Mental Health (NIMH) | Bipolar Disorder | 09/08 | 10/08 | | |
NCT03730857: Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics |
|
|
| Completed | 1 | 111 | NA | Olanzapine, second-generation antipsychotics, risperidone, Paliperidone, second-generationantipsychotics | Calo Psychiatric Center | Schizophrenia | 12/08 | 12/08 | | |
NCT01996488: Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition |
|
|
| Completed | 1 | | RoW | Olanzapine Orally Disintegrating Tablets 5mg | Torrent Pharmaceuticals Limited | Healthy | 01/09 | | | |
NCT01996501: Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition |
|
|
| Completed | 1 | | RoW | Olanzapine Orally Disintegrating 5mg Tablets | Torrent Pharmaceuticals Limited | Healthy | 01/09 | | | |
NCT00852956: Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects |
|
|
| Completed | 1 | 50 | Europe | Betahistine | OBEcure Ltd. | Healthy | 04/09 | 04/09 | | |
NCT00287352: Study of Amantadine for Weight Stabilization During Olanzapine Treatment |
|
|
| Completed | 1 | 40 | US | Olanzapine, Amantadine, Olanzapine and placebo | University of North Carolina, Chapel Hill, Eli Lilly and Company | Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features | 09/09 | 09/09 | | |
| Terminated | 1 | 1 | Canada | Escitalopram, Cipralex, placebo | Queen's University | Bipolar Depression | 01/10 | 01/10 | | |
NCT00977301: Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA) |
|
|
| Completed | 1 | 24 | Europe | fosamprenavir/ritonavir, olanzapine | Radboud University Medical Center, GlaxoSmithKline | HIV Infections | 08/10 | 08/10 | | |
NCT00567034: Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects |
|
|
| Completed | 1 | 30 | US | naltrexone, placebo | Mclean Hospital | Schizophrenia, Psychotic Disorders | 12/10 | 12/11 | | |
NCT01168336: Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects |
|
|
| Completed | 1 | 90 | Europe | Betahistine standard formulation, Betahistine Extended Release formulation, Placebo | OBEcure Ltd. | Healthy | 12/10 | 12/10 | | |
NCT01503424: Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study |
|
|
| Completed | 1 | 48 | RoW | Olanzapine, Zyprexa | Dr. Reddy's Laboratories Limited | Fed | 09/11 | 09/11 | | |
NCT01503398: Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions |
|
|
| Completed | 1 | 48 | RoW | Olanzapine, Zyprexa | Dr. Reddy's Laboratories Limited | Fasting | 09/11 | 09/11 | | |
| Completed | 1 | 96 | US | Metformin, glucophage, fortamet, glucophage xr, glumetza, riomet | Nationwide Children's Hospital | Obesity, Weight Gain, Psychotropic Induced Weight Gain | 02/12 | 05/13 | | |
NCT01607762: A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics |
|
|
| Completed | 1 | 31 | Europe | Aripiprazole, Quetiapine, Olanzapine, Risperidone, Paliperidone | Janssen Research & Development, LLC | Healthy | 04/12 | 10/12 | | |
NCT02087579: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants |
|
|
| Completed | 1 | 305 | US, Europe, RoW | Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, INVEGA®, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, RISPERDAL®, Risperidone, LAI | Janssen Research & Development, LLC | Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder | 10/14 | 12/14 | | |
NCT02447835: Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction |
|
|
| Completed | 1 | 15 | US | Olanzapine, Zyprexa | Michael Rickels, University of Pennsylvania | Normal Non-fluency | 12/14 | 12/14 | | |
NCT02181803: MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003) |
|
|
| Completed | 1 | 55 | NA | MK-8189, Placebo, Base Monotherapy | Merck Sharp & Dohme LLC | Schizophrenia | 04/15 | 04/15 | | |
NCT02634463: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone |
|
|
| Completed | 1 | 81 | Europe | Aripiprazole, Olanzapine, Paliperidone, Risperidone | Janssen Research & Development, LLC | Immunoassay, Antipsychotic | 11/16 | 11/16 | | |
CBD-IS, NCT02051387: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
|
| Completed | 1 | 74 | Europe | Cannabidiol CR, Arvisol, Cannabidiol, Amisulpride, Olanzapine, Quetiapine, Risperidone, Placebo | Central Institute of Mental Health, Mannheim, University of Cologne | Schizophrenia | 08/17 | 08/17 | | |
ChiCTR-IID-17011693: A phase I trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy |
|
|
| Recruiting | 1 | 40 | | 2.5mg, 5mg, 7.5mg, 10mg, 15mg | The General Hospital of the People's Liberation Army; The General Hospital of the People's Liberation Army, fundation of China anticancer association geriatric cancer Specialized Committee | Malignant tumor | | | | |
ACTRN12618000966291: A placebo and comparator controlled phase 1, safety and tolerability study of 3 ascending doses of INP105 (intranasal OLZ by I231 POD® device). |
|
|
| Completed | 1 | 36 | | | Clinical Network Services (CNS) Pty Ltd , Impel® NeuroPharma Inc. | Acute Agitation in Schizophrenia , Acute Agitation in Bipolar I Disorder | | | | |
SNAP 101, NCT03624322: Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - |
|
|
| Completed | 1 | 38 | RoW | Zyprexa IM, Zydis, Zyprexa Zydis, INP105, OLZ or placebo, I231 POD® Device, POD® | Impel NeuroPharma Inc. | Acute Agitation | 10/18 | 10/18 | | |
NCT03877562: The Effect of CORT118335 on Olanzapine-Induced Weight Gain |
|
|
| Completed | 1 | 96 | Europe | Olanzapine, CORT118335, Placebo | Corcept Therapeutics | Antipsychotic-induced Weight Gain | 03/20 | 03/20 | | |
NCT03565068: A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007) |
|
|
| Completed | 1 | 75 | US | MK-8189, Placebo, Background AAP Therapy | Merck Sharp & Dohme LLC | Schizophrenia | 04/20 | 04/20 | | |
NCT03790085: Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals |
|
|
| Unknown status | 1 | 2700 | RoW | Risperidone, Olanzapine, Aripiprazole | Tianjin Medical University General Hospital, Shanghai Mental Health Center, Nanjing Medical University, Tianjin Anding Hospital, Harbin First Specialist Hospital, First Affiliated Hospital of Chongqing Medical University, Anhui Mental Health Center, Wuhan Psychiatric Hospital, Wenzhou Seventh People's Hospital, First Affiliated Hospital of Harbin Medical University | Schizophrenia, Major Depressive Disorder, Anxiety Disorders | 06/20 | 12/20 | | |
NCT05123976: Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects. |
|
|
| Completed | 1 | 32 | RoW | Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine), Adagio film-coated tablets 5 mg (JSC Farmak, Ukraine), Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V), Olanzapine | Joint Stock Company "Farmak" | Pharmacokinetics | 11/20 | 11/20 | | |
NCT03781115: Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia |
|
|
| Recruiting | 1 | 24 | US | Ziprasidone, Geodon, Olanzapine, Zyprexa, Placebo Comparator, Placebo Oral Capsule | University of Arizona, Sidney R. Baer, Jr. Foundation | Schizophrenia | 12/22 | 01/23 | | |
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard |
|
|
| Completed | 1 | 31 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 09/23 | 09/23 | | |
NCT05857566: Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine |
|
|
| Completed | 1 | 24 | US | RDX-002 | Response Pharmaceuticals | Drug-induced Weight Gain | 07/23 | 09/23 | | |
NCT02708394: Molecular Mechanisms of Antipsychotic-induced Insulin Resistance |
|
|
| Completed | 1 | 31 | US | olanzapine, Zyprexa, placebo | Wayne State University | Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance | 10/23 | 10/23 | | |
NCT05542264: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia |
|
|
| Completed | 1 | 19 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 02/24 | 02/24 | | |
NCT06107803: A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia |
|
|
| Completed | 1 | 17 | US | Roluperidone 64 mg, MIN-101, Olanzapine 10 MG | Minerva Neurosciences | Negative Symptoms in Schizophrenia | 01/24 | 01/24 | | |
NCT06315283: An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia |
|
|
| Recruiting | 1 | 116 | US | TV-44749, Olanzapine, Oral olanzapine, ZYPREXA® | Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia | 04/25 | 04/25 | | |
NCT06253546: Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia |
|
|
| Recruiting | 1 | 36 | RoW | TV-44749, Oral Olanzapine, ZYPREXA | Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia | 01/25 | 01/25 | | |
NCT06319170: Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder |
|
|
| Recruiting | 1 | 95 | US | Olanzapine Extended Release, Olanzapine, ZYPREXA | Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia, Schizoaffective Disorder | 12/24 | 12/24 | | |
NCT03741478: Intranasal Insulin and Olanzapine Study in Healthy Volunteers |
|
|
| Recruiting | 1 | 64 | Canada | OLANZapine 2.5 MG, Mylan-Olanzapine, Placebo, Olanzapine Placebo, Insulin Lispro 100 UNT/ML, Intranasal Insulin, Saline | Centre for Addiction and Mental Health, University Health Network, Toronto | Healthy Controls | 07/24 | 07/24 | | |
LBL, NCT05964647: Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects |
|
|
| Recruiting | 1 | 20 | Europe | LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg), LSD (150 µg) + placebo, Placebo + placebo | University Hospital, Basel, Switzerland | Healthy | 06/25 | 06/25 | | |
